In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&U's Fred Hassan: The Virtue of "Been There, Done That"

Executive Summary

P&U managed to turn itself around following the near-disaster of its merger between Swedish Pharmacia and American Upjohn, with much of the credit due to its CEO and the subject of this interview, Fred Hassan. Hassan consolidated its autonomous research and marketing centers and focused development and marketing efforts on a few heretofore under-resourced drugs. He had the advantage of being new to the job, brought in to salvage an already bad situation. His experience with previous deals at American Home certainly helped. And he argues his consolidation experience will help with Monsanto, too--though now he's an insider trying to manage a merger of equals. But the central value of the P&U and P&U/Monsanto deal is the same: create a vastly increased marketing force to turbocharge the launch of the company's new products.

You may also be interested in...

Get Attitude, Drive Cultural Transformation, Fred Hassan Tells Execs At TAP

Cultural transformation was the main topic of Warburg Pincus managing director Fred Hassan’s keynote talk at the Therapeutic Area Partnerships meeting on Nov. 19, where the audience also drew on the investor’s extensive track record leading some of pharma’s most successful turnarounds.

Schering-Plough: What Went Wrong, What to Do

CEO Fred Hassan faults decentralization and financial over-management for much of Schering's trouble--including its inability to fix its manufacturing problems, its lack of oversight over its sales force, and its inadequate response to the competitive threat from Roche. Cutting costs further--as some analysts looking for short-term earnings growth would like to see--won't help. Instead, Hassan's investing-particularly in marketing-oriented clinical studies.

Newron Pharmaceuticals SPA

Starting out with a CNS research program left behind in the restructuring that created Pharmacia Corp., Newron Pharmaceuticals SPA has launched a program to develop ion channel-targeted drugs for epilepsy, neuropathic pain, Parkinson's disease and other neurodegenerative disorders.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts